检索结果-南通市图书馆

David ***:better tools to catch the vision thief

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Annals of Eye Science 2018年第1期 246-248页

作者： cheng-ying lin Tung-Lun Shih Annals of Eye Science

Expert introduction David ***(Figure 1)is Professor of Mechanical and Aerospace Engineering and Associate Director of Center for Advanced Microsystems Packaging at the Hong Kong University of Science and *** conducts basic research in nanocomposite and nanoporous material processing and development with applications in electronics *** applies the basic research results in the development of contact lens sensor for glaucoma and diabetes and develops thrombectomy and advanced coiling devices for strokes.

关键词： Director Expert Figure

A Comparison between Volume Responsiveness Predicted by Changes in Pulse Pressure and by Changes in Stroke Volume Induced by Passive Leg Raising

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

麻醉与监护论坛 2011年第2期18卷 114-118,121页

作者： Lei Huang Wei-xing Zhang Wen-xun Cai ying-qun cheng ying-xin lin Department of Intensive Care Unit Peking University Shenzhen Hospital Shenzhen Guangdong 518036 China

Gefitinib(an EGFR tyrosine kinase inhibitor)plus anlotinib(an multikinase inhibitor)for untreated,EGFR-mutated,advanced non-small cell lung cancer(FL-ALTER):a multicenter phase III trial

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2024年第9期9卷 4091-4102页

作者： Hua-Qiang Zhou Ya-Xiong Zhang Gang Chen Qi-Tao Yu Hua Zhang Guo-Wu Wu Di Wu ying-cheng lin Jun-Fei Zhu Jian-Hua Chen Xiao-Hua Hu Bin Lan Ze-Qiang Zhou Hai-Feng lin Zi-Bing Wang Xiao-lin Lei Suo-Ming Pan Li-Ming Chen Jian Zhang Tian-Dong Kong Ji-cheng Yao Xin Zheng Feng Li Li Zhang Wen-Feng Fang Department of Medical Oncology Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaGuangdong Provincial Clinical Research Center for CancerCollaborative Innovation Center for Cancer MedicineGuangzhou 510060China Department of Medical Oncology of Respirotary Affiliated Tumor Hospital of Guangxi Medical UniversityNanning 530021China Department of Urogenital Oncology the First People’s Hospital of FoshanFoshan 52800China Department of Medical Oncology Meizhou People’s Hospital(Huangtang Hospital)Meizhou 514031China Department of Respiratory and Critical Care Medicine Shenzhen people’s HospitalShenzhen 518020China Department of Medical Oncology of Respirotary Cancer Hospital of Shantou University Medical CollegeShantou 515031China Department of Respiratory and Critical Care Medicine Taizhou Central HospitalTaizhou 318000China Department of Medical Oncology Hunan Provincial Cancer HospitalChangsha 410031China Department of Medical Oncology the First Affiliated Hospital of Guangxi Medical UniversityNanning 530021China Department of Cardiothoracic Surgery Shantou Central HospitalShantou 515031China Department of Oncology the 2nd People’s Hospital of ShenzhenShenzhen 518025China Department of Medical Oncology the Second Affiliated Hospital of Hainan Medical UniversityHaikou 570216China Department of Immunotherapy Henan Cancer HospitalZhengzhou 450003China Department of Oncology Affiliated Hospital of Panzhihua UniversityPanzhihua 617099China Department of Radiotherapy Yuebei People’s HospitalShaoguan 512099China Department of Oncology the First Affiliated Hospital of Shantou University Medicine CollegeShantou 515041China Department of Oncology ZhuJiang Hospital of Southern Medical University(The Second Clinical Medical College)Guangzhou 510280China Department of Respiratory Oncology the Third People’s Hospital of ZhengzhouZhengzhou 450001China Shanghai OrigiMed Co. LtdShanghaiChina

Dual inhibition of vascular endothelial growth factor and epidermal growth factor receptor(EGFR)signaling pathways offers the prospect of improving the effectiveness of EFGR-targeted *** this phase 3 study(***:NCT04028778),315 patients with treatment-naïve,EGFR-mutated,advanced non-small cell lung cancer(NSCLC)were randomized(1:1)to receive anlotinib or placebo plus gefitinib once daily on days 1–14 per a 3-week *** the prespecified final analysis of progression-free survival(PFS),a significant improvement in PFS was observed for the anlotinib arm over the placebo arm(hazards ratio[HR]=0.64,95%CI,0.48–0.80,P=0.003).Particularly,patients with brain metastasis and those harboring EGFR amplification or high tumor mutation load gained significant more benefits in PFS from gefitinib plus *** incidence of grade 3 or higher treatment-emergent adverse events was 49.7%of the patients receiving gefitinib plus anlotinib versus 31.0%of the patients receiving gefitinib plus *** plus gefitinib significantly improves PFS in patients with treatment-naïve,EGFR-mutated,advanced NSCLC,with a manageable safety profile.

关键词： cancer lung treatment

Nanostructured ZnO/BiVO_(4)I-scheme heterojunctions for piezocatalytic degradation of organic dyes via harvesting ultrasonic vibration energy

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

International Journal of Minerals,Metallurgy and Materials 2025年第2期32卷 488-497页

作者： Yiling Li Xiaoyao Yu yingjie Zhou Yao lin ying Wu Key Laboratory of the Ministry of Education for Advanced Catalysis Materials College of Chemistry and Materials ScienceZhejiang Normal UniversityJinhua 321004China

BiVO_(4)porous spheres modified by ZnO were designed and synthesized using a facile two-step *** resulting ZnO/BiVO_(4)composite catalysts have shown remarkable efficiency as piezoelectric catalysts for degrading Rhodamine B(RhB)unde mechanical vibrations,they exhibit superior activity compared to pure *** 40wt%ZnO/BiVO_(4)heterojunction composite displayed the highest activity,along with good stability and *** enhanced piezoelectric catalytic activity can be attributed to the form ation of an I-scheme heterojunction structure,which can effectively inhibit the electron-hole ***,hole(h+)and superoxide radical(·O_(2)^(-))are proved to be the primary active ***,ZnO/BiVO_(4)stands as an efficient and stable piezoelectric catalyst with broad potential application in the field of environmental water pollution treatment.

关键词： piezoelectric catalytic heterojunction dye degradation ultrasonic vibration

Islet transplantation for diabetic rats through the spleen

在线全文

学校读者我要写书评

暂无评论

Hepatobiliary & Pancreatic Diseases International 2005年第2期4卷 203-206页

作者： ying cheng, Jia-lin Zhang, Yong-Feng Liu, Tie-Min Li and Ning Zhao Shenyang, China Organ Transplant Unit, First Affiliated Hospital of China Medical University, Shenyang 110001, China Organ Transplant Unit First Affiliated Hospital of China Medical University Shenyang 110001 China. chengying75@***

BACKGROUND: Islet transplantation is considered a po- tentially curative treatment for diabetic mellitus. The aim of this study was to assess the feasibility of islet transplant through the spleen. METHODS: Both donor and recipient Wistar rats (BW150± 20 g) were provided by the Animal Center of China Medi- cal University, Shenyang, China. Islets were isolated and purified with the modified Minnesota program. 600-800IE graft islets were handpicked and transplanted through the spleen of diabetic recipients. Blood glucose and insulin were evaluated after operation every other day. IVGTT was performed 10 days after transplantation. RESULTS: 300-400IE islet was procured from one donor rat. Secretion index (SI) of the glucose stress was 5.59± 0.62, showing the graft functioning well. The diabetic rats restored normal blood glucose levels of 3.4-5.4 mmol/L (mean 4.8 mmol/L). Their insulin levels were as normal as 8.5-12.2 μIU/ml. The K value of IVGTT in the rats after transplantation was similar to the normal one. CONCLUSIONS: The islets can be transplanted successfully through the spleen, while avoiding the complications caused by traditional transplantation through the portal vein, such as bleeding and portal vein hypertension. The graft islets loss can be reduced because of less centrifugation and mechanic pressure. In conclusion, transplantation through the spleen is a simple and feasible method.

关键词： islet transplantation spleen diabetes mellitus

Multi-model ensemble learning for battery state-of-health estimation:Recent advances and perspectives

在线全文

学校读者我要写书评

暂无评论

Journal of Energy Chemistry 2025年第1期100卷 739-759页

作者： Chuanping lin Jun Xu Delong Jiang Jiayang Hou ying Liang Zhongyue Zou Xuesong Mei State Key Laboratory for Manufacturing Systems Engineering Xi'an Jiaotong University Shaanxi Key Laboratory of Intelligent Robots School of Mechanical Engineering Xi'an Jiaotong University Department of Electrical Engineering and Automation Luoyang Institute of Science and Technology School of Mechanical Engineering Hangzhou Dianzi University

The burgeoning market for lithium-ion batteries has stimulated a growing need for more reliable battery performance monitoring. Accurate state-of-health(SOH) estimation is critical for ensuring battery operational performance. Despite numerous data-driven methods reported in existing research for battery SOH estimation, these methods often exhibit inconsistent performance across different application scenarios. To address this issue and overcome the performance limitations of individual data-driven models,integrating multiple models for SOH estimation has received considerable attention. Ensemble learning(EL) typically leverages the strengths of multiple base models to achieve more robust and accurate outputs. However, the lack of a clear review of current research hinders the further development of ensemble methods in SOH estimation. Therefore, this paper comprehensively reviews multi-model ensemble learning methods for battery SOH estimation. First, existing ensemble methods are systematically categorized into 6 classes based on their combination strategies. Different realizations and underlying connections are meticulously analyzed for each category of EL methods, highlighting distinctions, innovations, and typical applications. Subsequently, these ensemble methods are comprehensively compared in terms of base models, combination strategies, and publication trends. Evaluations across 6 dimensions underscore the outstanding performance of stacking-based ensemble methods. Following this, these ensemble methods are further inspected from the perspectives of weighted ensemble and diversity, aiming to inspire potential approaches for enhancing ensemble performance. Moreover, addressing challenges such as base model selection, measuring model robustness and uncertainty, and interpretability of ensemble models in practical applications is emphasized. Finally, future research prospects are outlined, specifically noting that deep learning ensemble is poised to advance ens

关键词： Lithium-ion battery State-of-health estimation Data-driven Machine learning Ensemble learning Ensemble diversity

胸腺肽α_1联合糖皮质激素冲击治疗难治性肾病综合征

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

中国临床研究 2010年第7期23卷 571-573页

作者：程英琳济南钢铁集团总公司总医院肾内科 250101

目的研究胸腺肽α1在大剂量糖皮质激素冲击治疗成人难治性肾病综合征(refractory nephrotic syndrome,RNS)过程中对肾病转归的影响及其对治疗过程中并发感染的防治作用。方法入选45例临床确诊的RNS病人,分为观察组24例与对照组21例,2组... 详细信息

目的研究胸腺肽α1在大剂量糖皮质激素冲击治疗成人难治性肾病综合征(refractory nephrotic syndrome,RNS)过程中对肾病转归的影响及其对治疗过程中并发感染的防治作用。方法入选45例临床确诊的RNS病人,分为观察组24例与对照组21例,2组基线资料均衡。观察组给予甲泼尼龙琥珀酸钠(MP)冲击联合胸腺肽α1治疗,MP冲击治疗1～3个疗程,如有效则渐转为维持量,3个疗程无效则放弃该疗法;胸腺肽α1疗程3个月。对照组仅MP冲击治疗1～3个疗程。比较2组病人治疗前后24h尿蛋白定量、血浆白蛋白、胆固醇3项指标的变化及治疗的总有效率、完全缓解率、显著缓解率、部分缓解率及感染率。观察期6个月。结果治疗后2组病人24h尿蛋白定量、血浆白蛋白、胆固醇3项指标较治疗前均有改善(P均0.05);感染发生率明显低于对照组(P<0.05)。结论胸腺肽α1能够增加机体抗感染能力,增强对激素冲击治疗的耐受力,双向调节RNS患者的免疫失衡,有效提高激素冲击治疗RNS的显著缓解率。

关键词：胸腺肽α1 糖皮质激素冲击疗法难治性肾病综合征免疫功能紊乱

血清Hcy、IL-6及hs-CRP水平在2型糖尿病肾病患者中的变化及临床意义

在线全文

学校读者我要写书评

暂无评论

中国医药指南 2012年第12期10卷 22-23页

作者：程英琳山东济南钢铁集团总公司总医院肾内科山东济南250101

目的探讨2型糖尿病肾病患者血清同型半胱氨酸(Hcy)、白介素-6(IL-6)和超敏C-反应蛋白(hs-CRP)水平的变化及其临床意义。方法选择2型糖尿病患者100例,根据尿白蛋白排泄率(UAER)分组,其中无白蛋白尿组(DM组)28例,早期糖尿病肾病组(DN1组)3... 详细信息

目的探讨2型糖尿病肾病患者血清同型半胱氨酸(Hcy)、白介素-6(IL-6)和超敏C-反应蛋白(hs-CRP)水平的变化及其临床意义。方法选择2型糖尿病患者100例,根据尿白蛋白排泄率(UAER)分组,其中无白蛋白尿组(DM组)28例,早期糖尿病肾病组(DN1组)34例,临床糖尿病肾病组(DN2组)38例,另选健康体检者30例作为对照组。采用ELISA法分别测定各组血清Hcy、IL-6水平,应用免疫比浊法测定血清hs-CRP水平。结果 2型糖尿病肾病患者组血清中Hcy IL-6及hs-CRP水平高于正常人组及DM组,且随糖尿病肾病的加重而增高,组间比较差异有显著性(P<0.05)。结论 Hcy IL-6及hs-CRP是2型糖尿病肾病的病理生理过程中重要的炎性介质,在2型糖尿病肾病的发生及发展过程中可能起重要作用。检测Hcy IL-6及hs-CRP有助于DN患者病情及预后的判断。

关键词：糖尿病肾病同型半胱氨酸白介素-6 超敏C-反应蛋白

NOX4 exacerbates Parkinson's disease pathology by promoting neuronal ferroptosis and neuroinflammation

在线全文

学校读者我要写书评

暂无评论

Neural Regeneration Research 2025年第7期20卷 2038-2052页

作者： Zhihao lin Changzhou ying Xiaoli Si Naijia Xue Yi Liu Ran Zheng ying Chen Jiali Pu Baorong Zhang Department of Neurology The Second Affiliated HospitalZhejiang University School of MedicineHangzhouZhejiang ProvinceChina

Parkinson's disease is primarily caused by the loss of dopaminergic neurons in the substantia nigra ***,a novel form of regulated cell death characterized by iron accumulation and lipid peroxidation,plays a vital role in the death of dopaminergic ***,the molecular mechanisms underlying ferroptosis in dopaminergic neurons have not yet been completely *** oxidase 4 is related to oxidative stress,however,whether it regulates dopaminergic neuronal ferroptosis remains *** aim of this study was to determine whether NADPH oxidase 4 is involved in dopaminergic neuronal ferroptosis,and if so,by what *** found that the transcriptional regulator activating transcription factor 3 increased NADPH oxidase 4 expression in dopaminergic neurons and astrocytes in an 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine-induced Parkinson's disease *** oxidase 4 inhibition improved the behavioral impairments observed in the Parkinson's disease model animals and reduced the death of dopaminergic ***,NADPH oxidase 4 inhibition reduced lipid peroxidation and iron accumulation in the substantia nigra of the Parkinson's disease model ***,we found that NADPH oxidase 4 interacted with activated protein kinase Cαto prevent ferroptosis of dopaminergic ***,by lowering the astrocytic lipocalin-2 expression,NADPH oxidase 4 inhibition reduced 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine-induced *** findings demonstrate that NADPH oxidase 4 promotes ferroptosis of dopaminergic neurons and neuroinflammation,which contribute to dopaminergic neuron death,suggesting that NADPH oxidase 4 is a possible therapeutic target for Parkinson's disease.

关键词： dopaminergic neuron ferroptosis NADPH oxidase 4(NOX4) neuroinflammation Parkinson's disease